Goldman Sachs has initiated coverage on Avidity Biosciences, a clinical-stage biotech company developing RNA therapeutics for muscular dystrophies, with a Buy rating and a $59 price target. The analyst sees significant commercial potential for Avidity’s lead assets, particularly del-brax for FSHD and del-desiran for DM1, both of which are poised to be first-to-market treatments.
CITGO Lemont Refinery and the Muscular Dystrophy Association (MDA) celebrated a record-breaking year at their 28th annual Driving for a Cure Golf Outing, raising over $900,000 to support MDA’s mission of empowering individuals with neuromuscular diseases. This event highlights the strong partnership between CITGO and MDA, which has raised over $9.2 million since its inception.
